GLP-1 nutrition in the age of GLP-1s: When appetite shrinks but responsibility expands

Abstract

Get full access to this article

View all access options for this article.

References

Amorim Moreira Alves

Teranishi

Teixeira de Castro Gonçalves Ortega

, et al. (2025) Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights. Medical Sciences (Basel, Switzerland) 13(3): 136.

Bettadapura

Dowling

Jablon

, et al. (2025) Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: Techniques and opportunities. International Journal of Obesity (2005) 49(3): 418–426.

Dias

Vasconcelos

Souza

ACR

, et al. (2025) Nutritional approaches to enhance GLP-1 analogue therapy in obesity: A narrative review. Obesities 5(4): 88.

Fitch

Gigliotti

Bays

(2025) Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obesity Pillars 16: 100205.

Gonzalez-Rellan

Drucker

(2025) The expanding benefits of GLP-1 medicines. Cell Reports. Medicine 6(7): 102214.

Hildebrand

Pfeifer

(2025) The obesity pandemic and its impact on non-communicable disease burden. Pflugers Archiv: European Journal of Physiology 477(5): 657–668.

Kerlikowsky

Krämer

Eggersdorfer

, et al. (2025) GLP-1 receptor agonists—Good for body weight, bad for micronutrient status? Current Developments in Nutrition 9(11): 107587.

Mozaffarian

Agarwal

Aggarwal

, et al. (2025) Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring, Md.) 33(8): 1475–1503.

QYD

Cox

McNeil

, et al. (2024) Obesity medications: A narrative review of current and emerging agents. Osteoarthritis and Cartilage Open 6(2): 100472.

10.

Sibal

Balamurugan

Langley

, et al. (2025) Macronutrient, micronutrient supplementation and monitoring for patients on GLP-1 agonists: Can we learn from metabolic and bariatric surgery? Nutrients 17(23): 3659.

11.

Ullah

Tamanna

(2025) Obesity: Clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies. Medicines 12(3): 19.

12.

Urbina

Salinas-Ruiz

Valenciano

, et al. (2026) Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: A narrative review. Clinical Obesity 16(1): e70070.

13.

Wilding

JPH

Batterham

Calanna

, et al. ; Step 1 Study Group (2021) Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine 384(11): 989–1002.

14.

World Health Organization (2026) Obesity and Overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:∼:text=Common%20health%20consequences,of%20developing%20NCDs%20in%20adulthood. (Accessed on 10^th April 2026).

15.

Zheng

Zong

, et al. (2024) Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy 9(1): Article 234.